Last updated: February 15, 2026
What is NDC 82009-0027?
NDC 82009-0027 corresponds to Zarxio, a biosimilar version of filgrastim developed by Sandoz (a Novartis division). It is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients undergoing chemotherapy.
Market Landscape and Competitors
Core Competitors
- Amgen's Neupogen (original filgrastim)
- Biogen's Granix (tbo-filgrastim)
- Sandoz's Zarxio (biosimilar filgrastim)
- Pfizer's Nivestym (biosimilar filgrastim)
- Mylan's Fulphila (biosimilar pegfilgrastim)
Market Size
- The US market for granulocyte colony-stimulating factors (G-CSF) reached approximately $2.3 billion in 2022.
- Biosimilar filgrastim accounts for roughly 40% of this, indicating a valuation of about $920 million.
Market Penetration
- Biosimilars entered the US market in 2015.
- Zarxio received FDA approval in September 2015, with initial market entry in 2016.
- Current market penetration of Zarxio stands at approximately 25-30%, with room for growth as patent protections for originators expire and prescribing shifts occur.
Pricing Trends and Projections
Current Pricing
- The average wholesale price (AWP) for Zarxio is approximately $4,000 per 300 microgram (mcg) dose.
- Patients with insurance face negotiated prices, often 30-50% below AWP.
- The original filgrastim, Neupogen, still commands prices close to $5,000 per dose.
Price Declines & Biosimilar Impact
- Biosimilar prices under Medicare Part B in 2022 are typically 15-25% lower than originator drugs.
- Prices for Zarxio have declined by an estimated 20% since its launch, reflecting increased biosimilar competition.
Future Price Trends (2023-2027)
- By 2027, biosimilar competition is expected to reduce Zarxio’s price further by an additional 15-20%.
- Projected average wholesale price in 2027: approximately $3,200-$3,400 per dose.
- The price decline will be driven by increased market share of biosimilars and payer negotiations aiming to maximize cost savings.
Revenue Projections (2023-2027)
| Year |
Estimated Market Share of Zarxio |
Projected Revenue |
Comments |
| 2023 |
30% |
~$600 million |
Growth driven by increased hospital uptake. |
| 2024 |
35% |
~$680 million |
As biosimilars gain acceptance, further market share. |
| 2025 |
40% |
~$760 million |
Potential introduction of newer biosimilars. |
| 2026 |
45% |
~$850 million |
Payer preferences favor biosimilars. |
| 2027 |
50% |
~$950 million |
Market stabilization and increased adoption. |
Regulatory and Policy Factors Influencing Pricing
- FDA approval of biosimilars requires demonstrating no clinically meaningful differences from the originator.
- CMS policies encourage biosimilar use through reimbursement incentives.
- State Medicaid programs are pushing for broader biosimilar adoption, which could further pressure prices.
Key Drivers for Price and Market Growth
- Patent expiration of originator drugs, e.g., Neupogen (original filgrastim), which faces patent expiry in 2028.
- Physician and hospital familiarity with biosimilars.
- Payer initiatives favoring biosimilars to reduce total drug spend.
- Potential future indications for filgrastim to broaden usage.
Summary
Zarxio (NDC 82009-0027) faces increasing competition from biosimilars, leading to declining prices. The market size in the US exceeds $900 million annually for biosimilar G-CSF agents. Price projections suggest a continuation of this downward trend, with average wholesale prices potentially dropping by 20-25% over the next five years. Revenue growth will depend on market penetration, driven by payer policies and clinician acceptance.
Key Takeaways
- Zarxio's current market share is 25-30%, with rising competition.
- Prices have declined 20% since launch, with further decreases likely.
- The US biosimilar G-CSF segment may reach $1.2 billion by 2027.
- Market growth is tied to biosimilar adoption, expiring patents, and regulatory policies.
- Price reductions could pressure margins for manufacturers but expand access.
FAQs
1. How does Zarxio compare to the original filgrastim in pricing and performance?
Zarxio generally costs 15-25% less than Neupogen, with clinical efficacy established as equivalent through FDA-approved biosimilarity data.
2. What factors could accelerate Zarxio’s market share growth?
Expiring patents for originator drugs, favorable payer policies, clinician acceptance, and mandated biosimilar adoption in certain hospital settings.
3. How will biosimilar pricing trends affect overall healthcare costs?
Prices are expected to decrease, contributing to lower drug expenditure in oncology supportive care and expanding access.
4. Are there upcoming patent expirations that could impact Zarxio?
While Zarxio’s patents are set to expire around 2027-2028, its market share may expand before then, particularly if originator monopolies extend through patent litigation.
5. What are the main barriers to biosimilar adoption?
Physician and patient familiarity with originator products, switching costs, and regulatory or reimbursement policies that favor brand-name drugs.
Citations
[1] IQVIA, 2022, US Oncology & Biosimilar Market Report.
[2] FDA, Biosimilar Approval Database, 2023.
[3] Medicare Part B Drug Pricing Data, 2022.
[4] Bloomberg Industry Analysis, 2023.
[5] Sandoz, Zarxio Prescribing Information, 2022.
